In these patients, the BRAF V600E mutation is associated with a worse prognosis, including higher clinical stage, tumor size, extra-thyroid extension, lymph-nodal metastases, tumor recurrence, and radiotherapy refractoriness [69]. This evidence concerns the gene BRAF and neoplasm.